KAZIA THERAPEUTICS LTD (KZIA) Form 424B3 — Aug 31, 2026
Kazia Therapeutics filed a 424B3 prospectus supplement dated August 31, 2026 that updates and supplements its prospectus dated December 22, 2025, which forms part of its Form F-1 registration statement (Registration No. 333-284606). The supplement incorporates the company's Form 6-K furnished to the SEC the same day. The prospectus covers 266,666 American Depositary Shares representing 133,333,000 ordinary shares, an implied ratio of 1 ADS to 500 ordinary shares.
Key figures
- Adss Covered
- 266666
- Implied Ads Ratio
- 1 ADS represents 500 ordinary shares (derived from cover-page share counts)
- Last Reported Sale Price
- $13.58 per ADS (Nasdaq, August 28, 2026)
- Ordinary Shares Represented
- 133333000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.